Compare IBP & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBP | CORT |
|---|---|---|
| Founded | 1977 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.7B |
| IPO Year | 2014 | 2001 |
| Metric | IBP | CORT |
|---|---|---|
| Price | $224.63 | $92.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $266.14 | $96.50 |
| AVG Volume (30 Days) | 425.9K | ★ 980.8K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 6.70 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $2,970,800,000.00 | $761,407,000.00 |
| Revenue This Year | $1.96 | $26.08 |
| Revenue Next Year | $4.32 | $26.98 |
| P/E Ratio | $176.95 | ★ N/A |
| Revenue Growth | 1.00 | ★ 12.79 |
| 52 Week Low | $182.88 | $28.66 |
| 52 Week High | $349.00 | $91.00 |
| Indicator | IBP | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 81.77 |
| Support Level | $195.46 | $76.41 |
| Resistance Level | $229.34 | N/A |
| Average True Range (ATR) | 9.05 | 3.76 |
| MACD | 2.63 | -0.02 |
| Stochastic Oscillator | 61.27 | 94.76 |
Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.